National Action Plan for Rare Diseases in Austria

1:1
Austria’s national strategy defining priority areas and concrete measures to improve care, research, and access to services for people living with rare diseases.

This publication presents Austria’s National Action Plan for Rare Diseases (NAP.se), developed on behalf of the Federal Ministry of Health. It defines nine strategic action areas covering governance, diagnosis, clinical care, research, information systems, patient involvement, and access to therapies, including objectives, proposed measures, responsible stakeholders, and indicative timelines. The publication is available in German only.

Acces this publication
Nationale Aktionsplan für seltene Erkrankungen

Year of publication

2015

ISBN

978-3-85010-538-5

Source

Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (Austria), Austrian Public Health Institute (Gesundheit Österreich GmbH – GÖG), National Coordination Centre for Rare Diseases (NKSE)

Author

Florian Bachner; Margit Gombocz; Claudia Habl; Joy Ladurner; Christine Leopold; Ursula Unterberger; Till Voigtländer

You might also be interested in

Conference "Advancement of Treatments for Rare Diseases" in Cyprus, June 2026

Cyprus conference connects European research priorities with the path to rare disease treatments

At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Call Text

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
ERDERA trainings template

ERDERA launches Ethics & Regulatory webinar series with introductory webinar on ethics across the research continuum

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
Situating ethics in the research continuum

Introductory webinar: Situating ethics in the research continuum

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.

ERDERA's

search form